Drug
Lurbinectedin
Lurbinectedin: highest development phase Phase 2, developed by Jazz Pharmaceuticals. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Jazz Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lurbinectedin NCT07459634 | Phase 2 | Extensive-stage Small-cell Lung Cancer |
| Lurbinectedin NCT05734066 | Phase 1/2 | Refractory Ewing Sarcoma |
| Lurbinectedin NCT05099666 | Phase 1/2 | Advanced Soft-tissue Sarcoma |
| Lurbinectedin NCT05244239 | Phase 1 | Extensive Stage Lung Small Cell Carcinoma |
Latest
Follow Lurbinectedin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.